APPLICATIONS PUBLISHED 7 APRIL 2004
Published: 1-Oct-2004
The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT). Further details on individual patent applications can be obtained from the EPO at Schottenfeldgasse 29, A-1072 Vienna. Tel: +43 1521 260 Fax: +43 1 52126 4492
The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT). Further details on individual patent applications can be obtained from the EPO at Schottenfeldgasse 29, A-1072 Vienna. Tel: +43 1521 260 Fax: +43 1 52126 4492
Pharmaceutical compsns of topic use, applied in treatment of skin and/or mucous injuries; use of compsns in treatment of skin and/or mucous injuries and use of compounds in skin and/or mucous injuries
Cristalia Produtos Quimicos e Farmaceuticos Ltda 1404281*
Sustained release drug delivery devices with coated drug cores
Bausch & Lomb 1404295*
Effervescent formulations of non-steroidal anti-inflammatory drugs
The Boots Company 1404296*
Reservoir device for intraocular drug delivery
The Johns Hopkins University School of Medicine 1404297*
A method for preparation of vesicles loaded with biological material
Yissum Research Development Company of the Hebrew University of Jerusalem 1404298*
Particles for inhalation having rapid release properties
Advanced Inhalation Research 1404299*
Pharmaceutical compsns of dispersions of drugs and neutral polymers
Pfizer Products 1404300*
Stable controlled release pharmaceutical compsns containing privastatin
Andrx Pharmaceuticals 1404301*
Pharmaceutical compsns of adsorbates of amorphous drugs
Pfizer Products 1404302*
Stable pharmaceutical compsns containing privastatin
Andrx Pharmaceuticals 1404303*
Tablet containing cetirizine and pseudoephedrine
UCB Farchim 1404304*
Pharmacological preparation made from a nanoparticulate mesomorphous polyelectrolyte lipid complex and at least one active ingredient
Fraunhofer-Gesellschaft zur Foerderung der angewandten Forschung 1404305*
A coated nicotine-containing chewing gum, manufacture and use thereof
Lindell, Katarina 1404306*
Estrogen receptor-related receptor alpha (ERR) agonist for inducing cartilage formation
Bonnelye, Edith; Aubin, Jane 1404307*
Treatment of disorders secondary to organic impairments
Snowden Pharmaceuticals 1404308*
A pharmaceutical combination comprising either (s)-2-ethoxy-3-4-(2-4-methane sulphonyl oxyphenyl ethoxy) phenyl] propionic acid or 3-4-2-(4-tert-butoxy carbonyl aminophenul) ethoxy] phenyl -(S)-2-ethoxy propanoic acid and a biguanide drug
AstraZeneca 1404309*
Orally administered dosage forms of GABA analogue prodrugs having reduced toxicity
Xenoport 1404310*
Wound treatment agent
Prontomed 1404311*
Carbamate compounds for use in the treatment of pain
Ortho-McNeill Pharmaceutical 1404312*
Methyl analogues of simvastatin as novel HMG-CoA reductase inhibitors
Ranbaxy Laboratories; Kumar, Yatendra 1404313*
Aerosol formulations of delta 8 tetrahydrocannabinol
Norton Healthcare 1404314*
Synergistic compsns of N-acyl-homoserine lactones and 4-quinolones
The University of Nottingham 1404315*
Cycloalkylpyrrole-3-carboxylic acid derivatives and heterocycloalkylpyrrole-3-carboxylic acid derivatives as GABA-A receptor ligands
Pfizer Products; Neurogen 1404316*
5-halo-tryptamine derivatives used as ligands of the 5-HT 6? and/or 5-HT 7? serotonin receptors
Sigma-Tau Industrie Farmaceutische Riunite 1404317*
Compounds and methods for regulating cell differentiation
The President and Fellows of Harvard College 1404318*
Novel metalloporphyrins and their use as radiosensitisers for radiation therapy
Brookhaven Science Association 1404319*
A pharmaceutical compsn comprising a nicotinic receptor partial antagonist and an antiemetic agent for modulating cholinergic function
Pfizer Products 1404320*
1-alkyl-2-aryl-benzimidazole derivatives, their use for producing medicaments and pharmaceutical preparations containing said derivatives
Schering 1404321*
1-butane acid derivatives, pharmaceutical compsns containing said derivatives, and the use thereof
Schebo Biotech 1404322*
Use of methylnaxetrone to treat immune suppression
The University of Chicago 1404323*
Prodrugs of gaba analogues, compsns and uses thereof
Xenoport 1404324*
Method for treating nerve injury caused by surgery
Guilford Pharmaceuticals; Johns Hopkins University School of Medicine 1404235*
Method of treating Parkinson's disease
Pharmacia & Upjohn 1404326*
Dermatological compsn comprising nicotinic acid or an amide and a sphingoid base
Dermaconcept JMC 1404327*
Alpha-hydroxyamide statine derivatives for the treatment of Alzheimer's disease
Elan Pharmaceuticals; Pharmacia & Upjohn 1404328*
Substituted 4-aryl-3-(3aryl-1-oxo-2-propenyl)-2(1H)-quinolinones and analogues as activators of caspases and inducers of apoptosis and the use thereof
Cytovia 1404329*
Substituted 8-arylquinoline PDE4 inhibitors
Merck Frosst Canada 1404330*
Sustained release formulations of oxymorphone
Penwest Pharmaceuticals 1404331*
Methods of making sustained release formulations of oxymorphone related applications
Penwest Pharmaceuticals 1404332*
Oxymorphone controlled release formulations
Endo Pharmaceuticals 1404333*
Targeted delivery of bioaffecting compounds for the delivery of cancer
Faulk Pharmaceuticals 1404334*
Amino nicotinase derivatives as glucokinase (GLK) modulators
AstraZeneca 1404335*
Compsns comprising CGMPPDE5 inhibitor for transdermal delivery to the erectile tissue of the penis
Bhattacharya, Sampad 1404336*
Quinazoline and pyrido 2,3-D]pyrimidine inhibitors of phosphodiesterase (PDE) 7
Bristol-Myers Squibb 1404337*
Adenosine analogues for the treatment of the insulin resistance syndrome and diabetes
Aventis Pharma Deutschland 1404338*
Method for treating fibrotic diseases or other indications VI
Alteon 1404339*
Naphthathiazine positive allosteric AMPA receptor modulators (PAARM)
Boehringer Ingelheim Pharma 1404340*
Active substance combination for medicamentous therapy of nicotine dependency
HF Arzneimittelforshchung 1404341*
Treatment of psychotic disorders comprising co-therapy with anticonvulsant derivatives and atypical antipsychotics
Ortho-McNeil Pharmaceutical 1404342*
Therapeutic combinations for the treatment of hormone deficiencies
Solvay Pharmaceuticals 1404343*
Bone anabolic compounds and methods
Anabonix; The Board of Trustees of the University of Arkansas 1404344*
Skin-permeable selective cyclooxygenase-2 inhibitor compsn
Pharmacia Corp 1404345*
Calcium phosphate delivery vehicles of osteoinductive proteins
Wyeth 1404346*
4'-substituted nucleosides for the treatment of diseases mediated by the hepatitis C virus
F Hoffmann-La Roche 1404347*
Compsns and methods for decreasing the risk of or preventing neural tube disorders in mammals
Insmed 1404348*
Fat-binding polymers
Genzyme 1404349*
Proteins associated with cell growth, differentiation, and death
Incyte Genomics 1404350*
Carbohydrate modifying agent and drinks containing the modifying agent
NXT; Corsini, Frank; Kozlenko, Richard' Vinson, Joe 1404351*
Environmentally safe insect repellant compsn
The 54 Group 1404352*
Methods of using a hyaluronan receptor
Weigel, Paul; Weigel, Janet 1404353*
Chemically-modified progenipoietin conjugates
Pharmacia 1404354*
Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
Nobex Corp 1404355*
CD10-activated prodrug compounds
Medarex 1404356*
Gonadotropin releasing hormone antagonists in gel-forming concentrations
Ferring 1404357*
Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof
PE Corp 1404358*
Methods of treatment involving human MDA-7
Board of Regents, The University of Texas System; Introgen Therapeutics 1404359*
Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof and methods of making same
Nobex Corp 1404360*
Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
Nobex Corp 1404361*
Signal-1/signal-2 bifunctional peptide inhibitors
University of Kansas 1404362*
Adjuvant compsn for mucosal and injection delivered vaccines
Gerber, Jay 1404363*
Sphingosine kinase interacts with TRAF2 and modulates tumour necrosis factor-induced cellular activity
Medvet Science 1404364*
Methods and compsns for inhibiting, preventing, or reducing tumour cell growth in patients resistant to the antineoplastic effects of antiestrogen therapy
A&G Pharmaceuticals 1404365*
Combination therapy of gamma-interferon and B cell specific antibodies
Intermune 1404366*
Use of polyclonal anti-HIV goat serum as a therapeutic agent
Ice Biologics 1404367*
Mutant forms of cholera holotoxin as an adjuvant
Wyeth Holdings; University of Colorado Health Science Centre 1404368*
Compsn comprising a PDE-4 inhibitor and H1-receptor antagonist and the use thereof for the manufacture of a medicament for the treatment of respiratory diseases
Glaxo Group 1404369*
Ophthalmic compsns comprising hyaluronic acid
Novartis 1404372*
PNA conjugate for the treatment of diseases associated with HIV
Deutsches Krebsforschungszentrum Stiftung des oeffentlichen Rechts 1404373*
SLC2As as modifiers of the P53 pathway and methods of use
Exelixis 1404374*
Imaging infection using fluorescent protein as a marker
Anticancer 1404375*
Radiopharmaceutical formulations
Bracco Imaging 1404376*
Improved chelator conjugates
Amersham 1404377*
Methods and apparatus relating to treatment systems using light for the treatment of fluid products
Purepulse Technologies 1404378*
Viral inactivation process using antioxidant
Gambro 1404379*
